+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Blood Preparation Market Size, Share & Trends Analysis Report By Product (Whole Blood, Blood Components, Blood Derivatives), Antithrombotic And Anticoagulants Type, By Application, And Segment Forecasts, 2019 - 2026

  • ID: 4773493
  • Report
  • 110 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca plc
  • Baxter International Inc
  • GlaxoSmithKline plc
  • Leo Pharma A/S
  • Pfizer, Inc
  • Sanofi
  • MORE
The global blood preparation market size is expected to reach USD 56.78 billion by 2026 registering a CAGR of 5.6%, according to this new report. Demand for transfusion of blood and its components and increasing prevalence of blood-related disorders are expected to fuel the growth of this market over the forecast period.

Increasing prevalence of thrombocytosis-associated disorders is also likely to boost market growth. According to the Centers for Disease Control and Prevention (CDC), around 900,000 individuals are affected by Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in U.S. each year, and 60,000-100,000 Americans die due to DVT/PE. Commercialization of drugs currently in the pipeline and introduction of new oral anticoagulants are expected to drive the market further.

Anticoagulants was the largest product segment in 2018 owing to increased R&D aimed at the development of novel prophylactic and therapeutic drugs. Re-launch of some key drug products, such as Urokinase in North America, are also likely to propel market growth over the coming years.

The market in Asia Pacific is also anticipated to witness high growth in future, owing to the presence of favorable government initiatives, sophisticated healthcare infrastructure, especially in Japan and Australia, and several untapped opportunities in the emerging markets of China and India.

Further key findings from the study suggest:
  • Whole blood product segment held the largest share in 2018 due increased number of surgeries and trauma cases
  • Blood derivatives is estimated to be the fastest-growing segment due to use of these products in patients affected with infectious diseases, such as Ebola
  • Anticoagulants dominated the antithrombotic and anticoagulants product segment and are likely to witness the fastest CAGR of 5.8% due to launch of novel and efficient anticoagulant drugs in market
  • The direct factor Xa inhibitors is the most lucrative segment on account of the introduction of new oral products, such as Xarelto, aimed at addressing unmet medical needs
  • Angina blood vessel complications was the largest application segment due to rise in lifestyle-associated diseases and popularity of oral anticoagulants
  • North America was the largest regional blood preparation market in 2018 and will maintain the dominance over the forecast years
  • Presence of sophisticated healthcare infrastructure along with high patient awareness and healthcare expenditure levels in North America will drive the regional market
  • Key companies in the market include GlaxoSmithKline PLC; Pfizer, Inc.; Baxter International, Inc.; Bristol-Myers Squibb Company; LEO Pharma A/S; Sanofi S.A.; Portola Pharmaceuticals, Inc.; and AstraZeneca PLC
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca plc
  • Baxter International Inc
  • GlaxoSmithKline plc
  • Leo Pharma A/S
  • Pfizer, Inc
  • Sanofi
  • MORE
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Market definition
1.3. Information procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information analysis
1.4.1. Data analysis models
1.5. Market formulation & data visualization
1.6. Data validation & publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Blood Preparation Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Product Pipeline Analysis, by Stage
3.3. Reimbursement Framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.5. Blood Preparation Market Analysis Tools
3.5.1. Industry Analysis - Porter’s
3.5.1.1. Supplier Power: Moderate
3.5.1.2. Buyer Power: Moderate
3.5.1.3. Substitution Threat: Low
3.5.1.4. Threat from new entrant: High
3.5.1.5. Competitive rivalry: High
3.6. PESTEL Analysis
3.6.1. Political Landscape
3.6.2. Environmental Landscape
3.6.3. Social Landscape
3.6.4. Technology Landscape
3.6.5. Legal Landscape

Chapter 4. Blood Preparation Market: Product Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Product market share analysis, 2018 & 2026
4.3. Product Dashboard
4.4. Global Blood Preparation Market, by Product, 2014 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
4.6. Whole Blood
4.6.1. Whole blood market, 2014 - 2026 (USD Million)
4.6.2. Red Cells
4.6.2.1. Red cells market, 2014 - 2026 (USD Million)
4.6.3. Granulocytes
4.6.3.1. Granulocytes market, 2014 - 2026 (USD Million)
4.6.4. Plasma
4.6.4.1. Plasma market, 2014 - 2026 (USD Million)
4.6.5. Platelets
4.6.5.1. Platelets market, 2014 - 2026 (USD Million)
4.7. Blood Components
4.7.1. Whole Blood Components
4.7.1.1. Whole blood components market, 2014 - 2026 (USD Million)
4.7.2. Packed Red Cells
4.7.2.1. Packed red cells market, 2014 - 2026 (USD Million)
4.7.3. Leukocyte Reduced Red Blood Cells
4.7.3.1. Leukocyte reduced red blood cells market, 2014 - 2026 (USD Million)
4.7.4. Frozen Plasma
4.7.4.1. Frozen plasma market, 2014 - 2026 (USD Million)
4.7.5. Platelet Concentrate
4.7.5.1. Plasma concentrate market, 2014 - 2026 (USD Million)
4.7.6. Cryoprecipitate
4.7.6.1. Cryoprecipitate market, 2014 - 2026 (USD Million)
4.8. Blood Derivatives
4.8.1. Blood derivatives market, 2014 - 2026 (USD Million)

Chapter 5. Antithrombotic and Anticoagulants Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type market share analysis, 2018 & 2026
5.3. Type Dashboard
5.4. Global Antithrombotic and Anticoagulants Market, by Type, 2014 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.6. Platelet Aggregation Inhibitors
5.6.1. Platelet aggregation inhibitors market, 2014 - 2026 (USD Million)
5.6.2. Glycoprotein Inhibitors
5.6.2.1. Glycoprotein inhibitors market, 2014 - 2026 (USD Million)
5.6.3. COX Inhibitors
5.6.3.1. COX inhibitors market, 2014 - 2026 (USD Million)
5.6.4. ADP Antagonists
5.6.4.1. ADP antagonists market, 2014 - 2026 (USD Million)
5.6.5. Others
5.6.5.1. Others market, 2014 - 2026 (USD Million)
5.7. Fibrinolytics
5.7.1. Fibrinolytics market, 2014 - 2026 (USD Million)
5.7.2. Tissue Plasminogen Activator (tPA)
5.7.2.1. Tissue Plasminogen Activator (tPA) market, 2014 - 2026 (USD Million)
5.7.3. Streptokinase
5.7.3.1. Streptokinase market, 2014 - 2026 (USD Million)
5.7.4. Urokinase
5.7.4.1. Urokinase market, 2014 - 2026 (USD Million)
5.8. Anticoagulants
5.8.1. Anticoagulants market, 2014 - 2026 (USD Million)
5.8.2. Heparins
5.8.2.1. Heparins market, 2014 - 2026 (USD Million)
5.8.2.2. Unfractionated Heparin
5.8.2.2.1. Unfractionated heparins market, 2014 - 2026 (USD Million)
5.8.2.3. Low Molecular Weight Heparin (LMWH)
5.8.2.3.1. Low Molecular Weight Heparin (LMWH) market, 2014 - 2026 (USD Million)
5.8.2.4. Ultra-low Molecular Weight Heparin
5.8.2.4.1. Ultra-low Molecular Weight Heparin market, 2014 - 2026 (USD Million)
5.8.3. Vitamin K antagonists
5.8.3.1. Vitamin K antagonists market, 2014 - 2026 (USD Million)
5.8.4. Direct thrombin inhibitors
5.8.4.1. Direct thrombin inhibitors market, 2014 - 2026 (USD Million)
5.8.5. Direct factor Xa inhibitors
5.8.5.1. Direct factor Xa inhibitors market, 2014 - 2026 (USD Million)

Chapter 6. Antithrombotic and Anticoagulants Market: Application Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Application market share analysis, 2018 & 2026
6.3. Application Dashboard
6.4. Global Antithrombotic and Anticoagulants Market, by Application, 2014 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
6.6. Thrombocytosis
6.6.1. Thrombocytosis market, 2014 - 2026 (USD Million)
6.7. Pulmonary embolism
6.7.1. Pulmonary embolism market, 2014 - 2026 (USD Million)
6.8. Renal impairment
6.8.1. Renal impairment market, 2014 - 2026 (USD Million)
6.9. Angina blood vessel complications
6.9.1. Angina blood vessel complications market, 2014 - 2026 (USD Million)
6.10. Others
6.10.1. Others market, 2014 - 2026 (USD Million)

Chapter 7. Blood Preparation Market: Regional Estimates & Trend analysis, by product,
7.1. Regional Market Snapshot
7.2. Regional Market Share and Leading Players, 2018 & 2026
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
7.5. North America
7.5.1. North America market, 2014 - 2026 (USD Million)
7.5.2. U.S.
7.5.2.1. U.S. market, 2014 - 2026 (USD Million)
7.5.3. Canada
7.5.3.1. Canada market, 2014 - 2026 (USD Million)
7.6. Europe
7.6.1. Europe market, 2014 - 2026 (USD Million)
7.6.2. U.K.
7.6.2.1. U.K. market, 2014 - 2026 (USD Million)
7.6.3. Germany
7.6.3.1. Germany market, 2014 - 2026 (USD Million)
7.6.4. Spain
7.6.4.1. Spain market, 2014 - 2026 (USD Million)
7.6.5. France
7.6.5.1. France market, 2014 - 2026 (USD Million)
7.6.6. Italy
7.6.6.1. Italy market, 2014 - 2026 (USD Million)
7.6.7. Russia
7.6.7.1. Russia market, 2014 - 2026 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific market, 2014 - 2026 (USD Million)
7.7.2. China
7.7.2.1. China market, 2014 - 2026 (USD Million)
7.7.3. Japan
7.7.3.1. Japan market, 2014 - 2026 (USD Million)
7.7.4. India
7.7.4.1. India market, 2014 - 2026 (USD Million)
7.7.5. South Korea
7.7.5.1. South Korea market, 2014 - 2026 (USD Million)
7.7.6. Singapore
7.7.6.1. Singapore market, 2014 - 2026 (USD Million)
7.7.7. Australia
7.7.7.1. Australia market, 2014 - 2026 (USD Million)
7.8. Latin America
7.8.1. Latin America market, 2014 - 2026 (USD Million)
7.8.2. Brazil
7.8.2.1. Brazil market, 2014 - 2026 (USD Million)
7.8.3. Mexico
7.8.3.1. Mexico market, 2014 - 2026 (USD Million)
7.8.4. Argentina
7.8.4.1. Argentina market, 2014 - 2026 (USD Million)
7.9. Middle East & Africa
7.9.1. Middle East & Africa market, 2014 - 2026 (USD Million)
7.9.2. South Africa
7.9.2.1. South Africa market, 2014 - 2026 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Saudi Arabia market, 2014 - 2026 (USD Million)
7.9.4. UAE
7.9.4.1. UAE market, 2014 - 2026 (USD Million)

Chapter 8. Antithrombotic and Anticoagulants Market: Regional Estimates & Trend analysis, by type & application,
8.1. Regional Market Snapshot
8.2. Regional Market Share and Leading Players, 2018
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
8.5. North America
8.5.1. North America market, 2014 - 2026 (USD Million)
8.5.2. U.S.
8.5.2.1. U.S. market, 2014 - 2026 (USD Million)
8.5.3. Canada
8.5.3.1. Canada market, 2014 - 2026 (USD Million)
8.6. Europe
8.6.1. Europe market, 2014 - 2026 (USD Million)
8.6.2. UK
8.6.2.1. UK market, 2014 - 2026 (USD Million)
8.6.3. Germany
8.6.3.1. Germany market, 2014 - 2026 (USD Million)
8.6.4. Spain
8.6.4.1. Spain market, 2014 - 2026 (USD Million)
8.6.5. France
8.6.5.1. France market, 2014 - 2026 (USD Million)
8.6.6. Italy
8.6.6.1. Italy market, 2014 - 2026 (USD Million)
8.6.7. Russia
8.6.7.1. Russia market, 2014 - 2026 (USD Million)
8.7. Asia Pacific
8.7.1. Asia Pacific market, 2014 - 2026 (USD Million)
8.7.2. China
8.7.2.1. China market, 2014 - 2026 (USD Million)
8.7.3. Japan
8.7.3.1. Japan market, 2014 - 2026 (USD Million)
8.7.4. India
8.7.4.1. India market, 2014 - 2026 (USD Million)
8.7.5. South Korea
8.7.5.1. South Korea market, 2014 - 2026 (USD Million)
8.7.6. Singapore
8.7.6.1. Singapore market, 2014 - 2026 (USD Million)
8.7.7. Australia
8.7.7.1. Australia market, 2014 - 2026 (USD Million)
8.8. Latin America
8.8.1. Latin America market, 2014 - 2026 (USD Million)
8.8.2. Brazil
8.8.2.1. Brazil market, 2014 - 2026 (USD Million)
8.8.3. Mexico
8.8.3.1. Mexico market, 2014 - 2026 (USD Million)
8.8.4. Argentina
8.8.4.1. Argentina market, 2014 - 2026 (USD Million)
8.9. Middle East & Africa
8.9.1. Middle East & Africa market, 2014 - 2026 (USD Million)
8.9.2. South Africa
8.9.2.1. South Africa market, 2014 - 2026 (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Saudi Arabia market, 2014 - 2026 (USD Million)
8.9.4. UAE
8.9.4.1. UAE market, 2014 - 2026 (USD Million)

Chapter 9. Company Profiles
9.1. Strategic Framework
9.1.1. GlaxoSmithKline plc
9.1.1.1. Company overview
9.1.1.2. Financial framework
9.1.1.3. Product benchmarking
9.1.1.4. Strategic initiatives
9.1.2. Pfizer, Inc
9.1.2.1. Company overview
9.1.2.2. Financial framework
9.1.2.3. Product benchmarking
9.1.2.4. Strategic initiatives
9.1.3. Bristol-Myers Squibb Company
9.1.3.1. Company overview
9.1.3.2. Financial framework
9.1.3.3. Product benchmarking
9.1.3.4. Strategic initiatives
9.1.4. Leo Pharma A/S
9.1.4.1. Company overview
9.1.4.2. Financial framework
9.1.4.3. Product benchmarking
9.1.4.4. Strategic initiatives
9.1.5. Sanofi
9.1.5.1. Company overview
9.1.5.2. Financial framework
9.1.5.3. Product benchmarking
9.1.5.4. Strategic initiatives
9.1.6. Xiamen Hisunny Chemical Co., LTD
9.1.6.1. Company overview
9.1.6.2. Financial framework
9.1.6.3. Product benchmarking
9.1.6.4. Strategic initiatives
9.1.7. AstraZeneca plc
9.1.7.1. Company overview
9.1.7.2. Financial framework
9.1.7.3. Product benchmarking
9.1.7.4. Strategic initiatives
9.1.8. Baxter International Inc
9.1.8.1. Company overview
9.1.8.2. Financial framework
9.1.8.3. Product benchmarking
9.1.8.4. Strategic initiatives
*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithKline plc
  • Pfizer, Inc
  • Bristol-Myers Squibb Company
  • Leo Pharma A/S
  • Sanofi
  • Xiamen Hisunny Chemical Co., LTD
  • AstraZeneca plc
  • Baxter International Inc
Note: Product cover images may vary from those shown
Adroll
adroll